Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-2173 in systemic lupus erythematosus
NCT06955598Phase 1Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Nov 2024
- Primary completion
- Nov 2025
- Modality
- Biological product
- Countries
- 1
01
Overview
Phase 1, open-label trial of SHR-2173 in systemic lupus erythematosus (SLE) (3 arms), sponsored by Hengrui Therapeutics. Primary endpoint: Adverse Events at 16 weeks. Started Nov 2024; status: completed.
02
Drugs
SHR-2173
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06955598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06955598.